CO6270370A2 - Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 - Google Patents
Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8Info
- Publication number
- CO6270370A2 CO6270370A2 CO10043417A CO10043417A CO6270370A2 CO 6270370 A2 CO6270370 A2 CO 6270370A2 CO 10043417 A CO10043417 A CO 10043417A CO 10043417 A CO10043417 A CO 10043417A CO 6270370 A2 CO6270370 A2 CO 6270370A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- vegf
- fragment
- antagonist
- angiogenesis
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 6
- 230000014399 negative regulation of angiogenesis Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 229960000397 bevacizumab Drugs 0.000 abstract 2
- 101000583209 Homo sapiens Prokineticin receptor 2 Proteins 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102100021204 cAMP-dependent protein kinase type II-alpha regulatory subunit Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Abstract
1.- Un método de tratamiento de tumores, que comprende administrar a un sujeto humano, que tiene un tumor tratado previamente con un antagonista del factor de crecimiento endotelial vascular (VEGF), una cantidad efectiva de un antagonista Bv8.2.- El método de la reivindicacion 1 en donde el tumor es resistente a tratamiento con el citado antagonista VEGF.3.- El método de la reivindicacion 1 en donde el antagonista VEGF es un anticuerpo anti-VEGF o un fragmento del mismo.4.- El método de la reivindicacion 3 en donde el anticuerpo anti-VEGF es bevacizumab o un fragmento o variante del mismo.5.- El método de la reivindicacion 1 en donde el antagonista Bv8 es un anticuerpo anti-Bv8 o un anticuerpo monoclonal de receptor anti-Bv8 o un fragmento del mismo.6.- El método de la reivindicacion 5 en donde el receptor Bv8 es PKR2/EG-VEGFR2.7.- El método de la reivindicacion 5 en donde el anticuerpo anti-Bv8 o anticuerpo monoclonal de receptor anti-Bv8 o un fragmento del mismo es quimérico, humanizado o humano.8.- El método de la reivindicacion 1 que comprende ademas administrar al citado sujeto humano un anticuerpo anti-VEGF.9.- El método de la reivindicacion 8 en donde el anticuerpo EGF es bevacizumab o un fragmento o variante del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97438207P | 2007-09-21 | 2007-09-21 | |
| US8307108P | 2008-07-23 | 2008-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270370A2 true CO6270370A2 (es) | 2011-04-20 |
Family
ID=40030248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10043417A CO6270370A2 (es) | 2007-09-21 | 2010-04-14 | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9284369B2 (es) |
| EP (1) | EP2203479B1 (es) |
| JP (1) | JP5615709B2 (es) |
| KR (1) | KR101578945B1 (es) |
| CN (1) | CN102037015B (es) |
| AR (1) | AR068532A1 (es) |
| AU (1) | AU2008302214B2 (es) |
| CA (1) | CA2700276A1 (es) |
| CL (1) | CL2008002782A1 (es) |
| CO (1) | CO6270370A2 (es) |
| ES (1) | ES2568881T3 (es) |
| IL (1) | IL204502A (es) |
| MX (1) | MX2010003013A (es) |
| NZ (1) | NZ584787A (es) |
| PE (1) | PE20091197A1 (es) |
| RU (2) | RU2471498C2 (es) |
| TW (1) | TWI457349B (es) |
| WO (1) | WO2009039337A2 (es) |
| ZA (1) | ZA201001868B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2386346T3 (es) * | 2001-08-29 | 2012-08-17 | Genentech, Inc. | Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena |
| NZ541480A (en) | 2003-03-12 | 2008-03-28 | Genentech Inc | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| CA2679867A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| MX2012001306A (es) * | 2009-07-31 | 2012-02-28 | Genentech Inc | Inhibicion de matastasis de tumor. |
| PL2488554T3 (pl) | 2009-10-14 | 2020-03-31 | Humanigen, Inc. | Przeciwciała przeciw epha3 |
| US8771685B2 (en) * | 2009-12-23 | 2014-07-08 | F. Hoffmann-La Roche Ag | Anti-BV8 antibodies and uses thereof |
| US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| WO2012171057A1 (en) | 2011-06-13 | 2012-12-20 | Csl Limited | Antibodies against g-csfr and uses thereof |
| KR20140068877A (ko) * | 2011-08-17 | 2014-06-09 | 제넨테크, 인크. | 불응성 종양에서의 혈관신생의 억제 |
| WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| US20150118215A1 (en) * | 2012-03-30 | 2015-04-30 | The General Hospital Corporation | Methods of Inhibiting Cell Proliferation |
| TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
| US20160030558A1 (en) * | 2013-03-13 | 2016-02-04 | Health Research, Inc. | Enhancement of vaccines |
| JP6553605B2 (ja) * | 2013-11-22 | 2019-07-31 | ジェムバックス アンド カエル カンパニー，リミティド | 血管新生抑制活性を有するペプチド、及びそれを含む組成物 |
| CN104237223B (zh) * | 2014-10-08 | 2017-04-12 | 江苏奥赛康药业股份有限公司 | 测定铁‑碳水化合物络合物中不稳定铁含量的方法 |
| CN104587469A (zh) * | 2015-01-19 | 2015-05-06 | 马洁 | G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用 |
| EP3384029B1 (en) * | 2015-12-03 | 2022-01-05 | National Health Research Institutes | Heterodimeric vascular endothelial growth factor and use thereof |
| WO2018108862A1 (en) * | 2016-12-12 | 2018-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer |
| ES2939461T3 (es) * | 2017-11-29 | 2023-04-24 | Csl Ltd | Método para tratar o prevenir la lesión por isquemia-reperfusión |
| NZ766484A (en) | 2018-01-26 | 2025-08-29 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| WO2019178645A1 (en) | 2018-03-23 | 2019-09-26 | Csl Limited | Method of treating asthma |
| KR20220104756A (ko) | 2019-11-25 | 2022-07-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제 |
| WO2025007195A1 (en) | 2023-07-05 | 2025-01-09 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| ES2386346T3 (es) * | 2001-08-29 | 2012-08-17 | Genentech, Inc. | Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CN1802169A (zh) * | 2003-03-12 | 2006-07-12 | 健泰科生物技术公司 | Bv8和/或EG－VEGF促进造血的用途 |
| NZ541480A (en) | 2003-03-12 | 2008-03-28 | Genentech Inc | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| CN101274098A (zh) | 2003-05-30 | 2008-10-01 | 健泰科生物技术公司 | 利用抗-vegf抗体的治疗 |
| US20080219985A1 (en) * | 2005-09-13 | 2008-09-11 | Thompson Penny J | Prok2 antagonists and methods of use |
| ITRM20070182A1 (it) * | 2007-04-03 | 2008-10-04 | Univ Roma | Antagonisti dei recettori delle prochineticine derivati di essi e loro uso |
-
2008
- 2008-09-17 CL CL2008002782A patent/CL2008002782A1/es unknown
- 2008-09-19 RU RU2010115755/15A patent/RU2471498C2/ru not_active IP Right Cessation
- 2008-09-19 WO PCT/US2008/076954 patent/WO2009039337A2/en not_active Ceased
- 2008-09-19 EP EP08832515.4A patent/EP2203479B1/en active Active
- 2008-09-19 ES ES08832515.4T patent/ES2568881T3/es active Active
- 2008-09-19 US US12/679,257 patent/US9284369B2/en not_active Expired - Fee Related
- 2008-09-19 JP JP2010525989A patent/JP5615709B2/ja not_active Expired - Fee Related
- 2008-09-19 NZ NZ584787A patent/NZ584787A/xx not_active IP Right Cessation
- 2008-09-19 KR KR1020107008635A patent/KR101578945B1/ko not_active Expired - Fee Related
- 2008-09-19 AU AU2008302214A patent/AU2008302214B2/en not_active Ceased
- 2008-09-19 CN CN200880117292.XA patent/CN102037015B/zh not_active Expired - Fee Related
- 2008-09-19 PE PE2008001642A patent/PE20091197A1/es not_active Application Discontinuation
- 2008-09-19 TW TW097136179A patent/TWI457349B/zh not_active IP Right Cessation
- 2008-09-19 CA CA2700276A patent/CA2700276A1/en not_active Abandoned
- 2008-09-19 MX MX2010003013A patent/MX2010003013A/es active IP Right Grant
- 2008-09-22 AR ARP080104117A patent/AR068532A1/es unknown
-
2010
- 2010-03-15 IL IL204502A patent/IL204502A/en not_active IP Right Cessation
- 2010-03-16 ZA ZA2010/01868A patent/ZA201001868B/en unknown
- 2010-04-14 CO CO10043417A patent/CO6270370A2/es not_active Application Discontinuation
-
2012
- 2012-09-19 RU RU2012140185/15A patent/RU2012140185A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI457349B (zh) | 2014-10-21 |
| CN102037015B (zh) | 2016-02-03 |
| NZ584787A (en) | 2012-12-21 |
| ES2568881T3 (es) | 2016-05-05 |
| RU2471498C2 (ru) | 2013-01-10 |
| AU2008302214B2 (en) | 2012-10-25 |
| IL204502A (en) | 2015-05-31 |
| KR101578945B1 (ko) | 2015-12-21 |
| JP2010540449A (ja) | 2010-12-24 |
| AU2008302214A1 (en) | 2009-03-26 |
| EP2203479A2 (en) | 2010-07-07 |
| KR20100075513A (ko) | 2010-07-02 |
| RU2012140185A (ru) | 2014-03-27 |
| US9284369B2 (en) | 2016-03-15 |
| ZA201001868B (en) | 2011-06-29 |
| WO2009039337A2 (en) | 2009-03-26 |
| HK1141538A1 (zh) | 2010-11-12 |
| JP5615709B2 (ja) | 2014-10-29 |
| TW200920750A (en) | 2009-05-16 |
| EP2203479B1 (en) | 2016-01-27 |
| CA2700276A1 (en) | 2009-03-26 |
| AR068532A1 (es) | 2009-11-18 |
| MX2010003013A (es) | 2010-08-02 |
| PE20091197A1 (es) | 2009-08-14 |
| US20100316633A1 (en) | 2010-12-16 |
| CN102037015A (zh) | 2011-04-27 |
| RU2010115755A (ru) | 2011-10-27 |
| CL2008002782A1 (es) | 2009-07-31 |
| WO2009039337A3 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270370A2 (es) | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| AR077595A1 (es) | Tratamientos de combinacion | |
| EA201170157A1 (ru) | Notch-связывающие агенты и антагонисты и способы их применения | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| AR066850A1 (es) | Dominio variable simple de inmunoglobulina contra el factor de crecimiento endotelial vascular (vegf) | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
| NZ626665A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| CO6440535A2 (es) | Antagonistas especificos del receptor fgf-r4 | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| JP2009522316A5 (es) | ||
| PE20201494A1 (es) | Anticuerpo anti-pacap | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |